Humulin 30/70 (Miscela)

Humulin 30/70 is a premixed insulin injection solution that contains human insulin at 100 IU/mL, composed of 30 % soluble (regular) insulin and 70 % intermediate‑acting NPH insulin. It is supplied in a sterile vial for subcutaneous use and is marketed in the European Union as a prescription‑only (Rx) product for the treatment of diabetes mellitus in adults and children who need a combined basal‑prandial insulin daily regimen therapy.

Humulin 30/70 is indicated for the glycemic control of patients with diabetes mellitus when a mixed insulin formulation is appropriate.

- Type 1 diabetes mellitus requiring both basal and prandial insulin coverage. - Type 2 diabetes mellitus inadequately controlled with oral agents alone. - Adults and pediatric patients who prefer fewer daily injections compared with separate basal and rapid‑acting insulins. - Situations where a predictable 30/70 ratio simplifies dose titration. - Use in combination with diet, exercise, and other antidiabetic medications as part of a comprehensive management plan.

Adverse reactions to Humulin 30/70 may vary in frequency and severity.

Common: - Mild hypoglycemia, especially if meals are missed or delayed. - Injection‑site redness, swelling, or itching. - Lipodystrophy presenting as localized thickening or thinning of subcutaneous tissue. - Transient weight gain due to fluid retention.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms (confusion, seizures, loss of consciousness). - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Persistent or worsening edema and heart failure exacerbation.

Clinicians should consider several precautions when prescribing Humulin 30/70 to ensure safe and effective use.

- Assess renal and hepatic function, as impairment can prolong insulin action and increase hypoglycemia risk. - Adjust doses during periods of illness, reduced food intake, or increased physical activity. - Monitor blood glucose closely during pregnancy; insulin requirements may change rapidly. - Avoid use in patients with known hypersensitivity to human insulin or any excipients in the formulation. - Educate patients on proper injection technique and rotation of sites to prevent lipohypertrophy. - Review concomitant medications that may mask hypoglycemia symptoms, such as beta‑blockers.

Humulin 30/70 can interact with other drugs, affecting glucose control or insulin pharmacodynamics.

Avoid: - Concurrent use of other rapid‑acting insulins or concentrated insulin formulations without dose adjustment. - MAO‑B inhibitors that may potentiate hypoglycemic episodes.

Use with caution: - Beta‑blockers, which can blunt hypoglycemia warning signs. - Thiazide diuretics and corticosteroids, which may raise blood glucose and require insulin dose increases. - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk when combined with premixed insulin. - Alcohol, especially in excess, because it can cause delayed hypoglycemia.